MedTrace Logo

Dapansutrile in Diabetes and Diabetes-Related Complications - Dapan-Dia

NCT06047262 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2026-02-25

No results posted yet for this study

Summary

The aim of the study is to determine whether NLRP3 inhibition with dapansutrile represents a new pharmacological option for diabetes management with potential as an anti-inflammatory agent to also address micro- and macro-vascular risk and complications from diabetes.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Dapansutrile

Patients receive investigational product.

DRUG

Placebo

Patients receive placebo.

Sponsors & Collaborators

  • European Union (Horizon Europe Programme)

    collaborator UNKNOWN

  • State Secretariat for Education Research and Innovation, Switzerland

    collaborator OTHER

  • Olatec Therapeutics LLC

    collaborator INDUSTRY

  • Departement Klinische Forschung Universität Basel

    collaborator UNKNOWN

  • CTU Kantonsspital Baden

    collaborator UNKNOWN

  • Marc Donath

    lead OTHER

Principal Investigators

  • Marc Y. Donath, Prof. · Kantonsspital Baden, Switzerland

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-09
Primary Completion
2028-07-31
Completion
2028-07-31

Countries

  • Belgium
  • France
  • Germany
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06047262 on ClinicalTrials.gov